Retrospective Analysis of Real-World Outcomes of Chronic/ Small Lymphocytic Leukemia (CLL/SLL) Patients Treated With First-Line Ibrutinib Versus Chemoimmunotherapy (CIT)

被引：0
|
作者：
Ran, Tao [1 ]
He, Jinghua [1 ]
Wu, Linda [2 ]
Panjabi, Sumeet [1 ]
Lu, Xiaoxiao [2 ]
机构：
[1] Janssen Sci Affairs, Titusville, FL USA
[2] Janssen Sci Affairs, Horsham, PA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷
关键词：
CLL; chronic lymphocytic leukemia/small lymphocytic leukemia; ibrutinib; chemoimmunotherapy; time to next treatment; real-world evidence;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CLL-345
引用
收藏
页码：S275 / S276
页数：2
相关论文
共 50 条
  • [1] Real-World Outcomes with First-Line Ibrutinib (Ibr) Versus Chemoimmunotherapy (CIT) in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Final Analysis Results from the InformCLL Registry
    Ghosh, Nilanjan
    Sharman, Jeff P.
    Barrientos, Jacqueline C.
    Brander, Danielle
    Gutierrez, Meghan
    Wu, Linda
    Qureshi, Zaina P.
    Upasani, Sandhya
    Naganuma, Maoko
    Mato, Anthony R.
    [J]. BLOOD, 2022, 140 : 7047 - 7049
  • [2] Real-world clinical outcomes in patients receiving either ibrutinib or chemoimmunotherapy (CIT) as first-line (1L) treatment for chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL): A retrospective analysis.
    Wu, Linda
    Ran, Tao
    He, Jinghua
    Panjabi, Sumeet
    Lu, Xiaoxiao
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] REAL-WORLD ECONOMIC OUTCOMES OF FIRST-LINE (1L) IBRUTINIB TREATMENT IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL)
    Challagulla, S.
    Lee, P.
    Kistler, K.
    Douyon, L.
    Lai, D.
    Iyengar, R.
    [J]. VALUE IN HEALTH, 2021, 24 : S38 - S38
  • [4] Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status
    Qing Huang
    Kathleen L. Deering
    Qing Harshaw
    Lori A. Leslie
    [J]. Advances in Therapy, 2022, 39 : 3292 - 3307
  • [5] Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status
    Huang, Qing
    Deering, Kathleen L.
    Harshaw, Qing
    Leslie, Lori A.
    [J]. ADVANCES IN THERAPY, 2022, 39 (07) : 3292 - 3307
  • [6] Real-world outcomes following adverse events and dose reduction of first-line ibrutinib in Medicare beneficiaries with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
    Shadman, Mazyar
    Srivastava, Bhavini P.
    Salkar, Monika
    Saifan, Chadi
    Agatep, Barnabie C.
    Jones, Barton
    Ryan, Olga
    Bacchus, Shaffee
    Stephens, Deborah M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Real-world treatment outcomes in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were treated with first-line single-agent ibrutinib vs chemoimmunotherapy
    Wang, Ruibin
    Ding, Zhijie
    Lu, Xiaoxiao
    Mavani, Heena
    He, Jinghua
    Qureshi, Zaina
    Pinilla, Javier
    [J]. LEUKEMIA & LYMPHOMA, 2023, 64 : S170 - S170
  • [8] Real-World Treatment Outcomes in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Were Treated With First-Line Single-Agent Ibrutinib vs Chemoimmunotherapy
    Wang, Ruibin
    Ding, Zhijie
    Lu, Xiaoxiao
    Mavani, Heena
    He, Jinghua
    Qureshi, Zaina
    Pinilla, Javier
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S330 - S330
  • [9] Clinical Outcomes Among Real-World Patients with Chronic Lymphocytic Leukemia (CLL) Initiating First-Line Ibrutinib or Chemoimmunotherapy (CIT) Stratified By Risk Status: Results from a US Retrospective Chart Review Study
    Qing Huang
    Deering, Kathleen L.
    Harshaw, Qing
    Bhagnani, Tarun
    Leslie, Lori A.
    [J]. BLOOD, 2020, 136
  • [10] Real-world treatment outcomes in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were treated with first-line single-agent ibrutinib vs. chemoimmunotherapy
    Wang, Ruibin
    Ding, Zhijie
    Lu, Xiaoxiao
    Mavani, Heena
    He, Jinghua
    Qureshi, Zaina P.
    Pinilla-Ibarz, Javier
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345